Theralase Technologies Inc.
TLTFF
Rank in Stocks
#23485
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages... Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research, development, and commercialization of light activated photo dynamic compounds and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. The company operates through Drug Division and Device Division segments. It designs, develops, manufactures, and markets super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ. Further, it researches, develops, manufactures, and distributes controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100 to healthcare practitioners primarily for the healing of pain. The company has a collaboration with the National Microbiology Laboratory, a Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. Theralase Technologies Inc. is based in Toronto, Canada.
Share Price
$0.1306
Last synced: 2026-11-09
Market Cap
$41.77M
Change (1 day)
0.46%
Change (1 year)
-12.93%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Theralase Technologies Inc. (TLTFF)
Category
Healthcare
EPS for Theralase Technologies Inc. (TLTFF)
EPS as of June 2026 TTM: $-0.01
According to Theralase Technologies Inc.'s latest financial reports, its current EPS (TTM) is $-0.01. At the end of 2025 the company had an EPS of $-0.01, equal to its 2024 EPS of $-0.01.
EPS history for Theralase Technologies Inc. from 2001 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.01 | 2.00% |
| 2025 | $-0.01 | -4.88% |
| 2024 | $-0.01 | -21.66% |
| 2023 | $-0.02 | -15.59% |
| 2022 | $-0.02 | 8.77% |
| 2021 | $-0.02 | -20.47% |
| 2020 | $-0.02 | -45.43% |
| 2019 | $-0.04 | 108.47% |
| 2018 | $-0.02 | -51.54% |
| 2017 | $-0.04 | 16.07% |
| 2016 | $-0.03 | -14.07% |
| 2015 | $-0.04 | 31.65% |
| 2014 | $-0.03 | 30.84% |
| 2013 | $-0.02 | -34.39% |
| 2012 | $-0.03 | -1.14% |
| 2011 | $-0.04 | 14.01% |
| 2010 | $-0.03 | 372.31% |
| 2009 | $-0.01 | -75.10% |
| 2008 | $-0.03 | -19.20% |
| 2007 | $-0.03 | 342.47% |
| 2006 | $-0.01 | -2,533.33% |
| 2005 | 0.00 | -83.33% |
| 2004 | 0.00 | -194.74% |
| 2003 | 0.00 | 26.67% |
| 2002 | 0.00 | -71.70% |
| 2001 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $2.70 | -26,570.59% |
US
|
|
| $4.09 | -40,198.04% |
IE
|
|
| $9.45 | -92,747.06% |
US
|
|
| $2.37 | -23,335.29% |
US
|
|
| $1.77 | -17,452.94% |
US
|
Questions about Theralase Technologies Inc.'s earnings per share (EPS)
What is Theralase Technologies Inc.'s earnings per share (EPS)?
Theralase Technologies Inc.'s earnings per share (EPS) over the last twelve months is $-0.01, as of Jun 2026.
What was Theralase Technologies Inc.'s earnings per share (EPS) in 2025?
In 2025, Theralase Technologies Inc.'s earnings per share (EPS) was $-0.01, compared with $-0.01 in 2024.
How has Theralase Technologies Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Theralase Technologies Inc.'s earnings per share (EPS) was highest in 2025 ($-0.01) and lowest in 2023 ($-0.02).
How does Theralase Technologies Inc.'s earnings per share (EPS) compare with similar companies?
Theralase Technologies Inc.'s earnings per share (EPS) ($-0.01) is lower than that of all 5 similar companies listed above. The highest among them is Stryker Corporation, with $9.45.